Evaluation of metrological characteristics of spectrophotometric quantitative determination of paracetamol in tablets by specific absorbance

Authors

  • O. A. Yevtifieieva National University of Pharmacy, Ukraine
  • K. I. Proskurina National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/nphj.14.1999

Keywords:

paracetamol, quantitative determination, spectrophotometry, specific absorbance method, validation

Abstract

The validation characteristics of the spectrophotometric quantitative determination of paracetamol in tablets by specific absorbance according to the British Pharmacopoeia (BPh) have been evaluated. The results of paracetamol content of 83.59% and 84.39% in terms of the average mass of one tablet do not meet the permissible limits B ±5.0%. The peculiarities of the sample preparation method for quantitative determination of the active pharmaceutical ingredient in tablets has been discussed, and comparative analysis of “Dissolution” and “Assay” tests for paracetamol tablets according to the BPh has been conducted. We have suggested to make such changes at the stage of the sample preparation as “… place the flask in an ultrasonic bath for 30 min…” instead of “…shake for 15 minutes…”. The acceptance criteria of the assay method for paracetamol tablets have been calculated for permissible limits of ±5.0%, ±7.5%, ±10.0%. The results of the convergence and linearity research of the method meet requirements for the permissible limits of ±5.0%. The results of the intermediate precision re-search of the method meet requirements for the permissible limits of ±7.5%. The results of the accuracy research of the method meet requirements for the permissible limits of ±10.0%. Taking into account the technical capabilities of the Ukrainian producers and a diverse list of excipients used in the manufacture of the drug, the spectrophotometric quantitative determination of paracetamol tablets by specific absorbance is recommended to use with the permissible limits of ±10.0%. The prognosis of the total uncertainty of the analysis results is consistent with requirements to the maximum permissible uncertainty of the analysis  Δ10.0%As = 2.6 ≤ max Δ10.0%As= 3.2% and with results of the 3rd round of the Professional Testing Programme (PTP) of “Pharma-test” laboratories in the system of the State Inspection for Medication Quality Control of the Ministry of Public Health of Ukraine.

Author Biography

O. A. Yevtifieieva, National University of Pharmacy

 

References

Габинет Е., Тедер К., Меос А. // Фармация. – 2011. – №2. – С. 8-11.

Головенко М.Я., Баула О.П., Борисюк І.Ю. Біофармацевтична класифікаційна система. – Л., 2010. – 299 с. 3. Государственная фармакопея Республики Беларусь. В 3-х т. Т.

Контроль качества фармацевтических субстанций / УП Центр экспертиз и испытаний в здравоохранении; под общ. ред. А.А.Шерякова. – Мн: Минский государственный ПТК полиграфии им. В.Хоружей, 2009. – 728 с.

Гризодуб А.И., Евтифеева О.А., Проскурина К.И., Безумова Е.В. // Фармаком. – 2014. – №1. – С. 29-39.

Гризодуб А.И., Зволинская Н.Н., Архипова Н.Н. и др. // Фармаком. – 2004. – №2. – С. 20-34.

Гризодуб О.І., Євтіфєєва О.А., Проскуріна К.І. // Фармаком. – 2012. – №3. – С. 7-30.

Державна фармакопея України / Державне підприємство «Науково-експертний фармакопейний центр». – 1-е вид. – Х.: РІРЕГ, 2001. – С. 556 с., Доп. 1. – Х.: РІРЕГ, 2004. – 520 с. Доп. 2. – Х.: РІРЕГ, 2008. – 608 с.

Євтіфєєва О.А. // Укр. журн. клін. та лаб. мед. – 2012. – Т. 7, №3. – С. 229-235.

British Pharmacopoeia [Електронний ресурс]. / The British Pharmacopoeia Secretariat. – London, 2009. – Vol. 1. – Р. 10952. Режим доступу: http://www.vek-com.ru/78022.html.

Burke A., Smyth E.M., Fitzgerald G.A. Analgesic-antipyretic agents; Pharmacotherapy of gout // In: Brunton L.L., Lazo J.S., Parker K.L. Ed. Goodman and Gilman′s. The Pharmacological Basis of Therapeutics. – 11th ed. – New York: Mcgraw-Hill, 2006. – Р. 671-716.

European Pharmacopoeia. 6th ed. – Strasbourg: European Directorate for the Quality of Medicines, 2008. – Vol. 2. – 3308 p.

Ganzewinkel C., Mohns T., Lingen R. et al. // J. of Med. Case Reports. – 2012. – Vol. 6, Iss. 1. Electronic version: http://www.jmedicalcasereports.com/content/6/1/1.

Pharmacopoeia Commission of the Ministry of Health of the People’s Republic of China. Pharmacopoeia of the People’s Republic of China. 9th ed. – China Medical Science and Technology Press, 2010. – Vol. 1. – P. 760.

The Japanese Pharmacopoeia. 16th ed. [Электронный ресурс]. Ministry of Health, Labour and Welfare of Japan. Режим доступу: http://jpdb.nihs.go.jp/jp16e.

The Korean Pharmacopoeia. 10th ed. [Электронный ресурс]. http://www.mfds.go.kr/eng/index.do?nMenuCode=50.

The USP Pharmacists’ Pharmacopoeia. 2nd ed. – Rockville, 2008. – 1519 p.

WHO 2005. WHO Model List of Essential Medicines. 14th ed. – World Health Organization, http:whqlibdoc.who.int/hq/2005/a87017_eng.pdf.

Yevtifieieva O., Proskurina K., Dynnyk K. // Вісник фармації. – 2014. – №1. – С. 44-48.

Downloads

Published

2014-12-01

Issue

Section

Synthesis and Analysis of Biologically Active Substances